New hope for young AML patients: drug cocktail targets resistant cancer
NCT ID NCT05317403
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether adding the drug venetoclax to a standard chemotherapy regimen can help children and young adults whose acute myeloid leukemia (AML) has come back or not responded to treatment. About 40 participants will receive different doses of venetoclax along with other drugs to see what dose is safe and whether it improves response. The goal is to find a better way to control this aggressive cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Venetoclax (a targeted cancer drug) combined with azacitidine, vorinostat, and cytarabine (chemotherapy)
What this could lead to
If successful, this could lead to a more effective treatment option for children and young adults with hard-to-treat AML that has returned or not responded to standard therapy.
What could go wrong
This is a very early phase 1 trial with only 40 participants, focused on finding a safe dose. It is not yet known if the combination works better than existing treatments, and there are risks of serious side effects from the drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA REFRACTORY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact